Unitree Robotics, the Chinese maker of humanoid and quadruped robots, has won regulatory approval for an initial public offering worth approximately $619 million on Shanghai's STAR Market — clearing the way for what will be the first "embodied AI" listing on China's A-share market. The China Securities Regulatory Commission signed off on July 3, 2026, and a debut could come as early as late July.
Here's what the IPO actually involves, what Unitree makes, and whether you can buy in.
What is Unitree?
Unitree was founded in Hangzhou in August 2016 by Wang Xingxing, an engineer who built his first bipedal robot as a college student for about ¥200 in parts. He started the company with roughly $275,000 in angel funding out of a 50-square-meter office.
The company makes two categories of robots:
- Quadrupeds — robot dogs, starting with the Go1 in 2021, which undercut Boston Dynamics' $75,000 Spot by launching at around $2,700. Unitree now holds close to 60% of the global quadruped robot market.
- Humanoids — bipedal robots, beginning with the H1 and its 2024 successor, the G1, priced around $16,000. Unitree delivered more than 5,500 humanoid robots in 2025, the most of any manufacturer worldwide, for a 32.4% global market share.
Financially, Unitree posted 1.7 billion yuan (about $250 million) in 2025 revenue, with roughly 591 million yuan in adjusted net profit and a gross margin above 60% on its core hardware lines — figures that make it one of the few humanoid robotics companies actually generating meaningful profit rather than burning cash on a pre-revenue story.
The IPO
The mechanics, as verified through CSRC and Shanghai Stock Exchange disclosures:
- Size: Approximately 4.2 billion yuan, or $618–619 million
- Exchange: Shanghai Stock Exchange's STAR Market (China's Nasdaq-style board for tech and "hard-tech" companies)
- Structure: A minimum of 40.4 million shares, representing at least a 10% stake
- Implied valuation: Roughly 42 billion yuan, or about $6.2 billion
- Status: CSRC approved the listing registration on July 3, 2026; underwriting, pricing, and share subscription details are still being finalized
- Timeline: Unitree filed on March 20, 2026, and cleared the listing committee in early June — a 73-day regulatory process, among the fastest on record for the STAR Market. The approval is valid for 12 months.
Unitree says proceeds will fund development of robot "brains" (AI and control systems), further R&D on robot bodies, and new product lines — a signal that the company sees the hardware business as a platform for a broader embodied-AI push rather than an endpoint in itself.
Can you buy Unitree stock?
Not the way you'd buy a US-listed IPO. The STAR Market is largely closed to retail investors outside mainland China — access is generally limited to domestic Chinese investors and Qualified Foreign Institutional Investors (QFII) with the right licensing.
For most international investors, indirect exposure is the realistic path: China-focused ETFs that track STAR Market or broader Chinese tech indices (some analysts have flagged funds like KraneShares' KSTR and the humanoid-robotics-focused KOID as vehicles likely to gain exposure once Unitree lists) may add the stock post-IPO. There is no US ADR or Nasdaq/NYSE listing planned as part of this offering.
Why it matters
Unitree's approval lands at a pointed moment. Humanoid and quadruped robotics has been one of the most heavily funded corners of physical AI in 2026, with venture capital pouring into the sector on the bet that embodied AI is the next platform shift after chatbots and copilots. Unitree going public — with actual revenue and profit, not just a roadmap — is the first real market test of what that hype is worth in public-market terms.
It also marks a divergence in how the humanoid robotics race is being financed. In the US, companies like Figure and Apptronik have stayed private, raising nine- and ten-figure venture rounds instead of listing. China's STAR Market, by design, exists to fast-track "hard-tech" companies to public capital — and a 73-day approval process shows regulators actively clearing the runway for robotics to get there. If Unitree's public debut prices well, expect more Chinese robotics and embodied-AI companies to follow the same path rather than staying dependent on venture funding rounds.
For now, Unitree is a bellwether: the first place public markets get to put a number on humanoid robotics, rather than relying on the private valuations venture investors have been assigning it.
Tracking every major raise and listing in AI? Wortins' AI Funding Tracker covers the rounds, IPOs, and valuations shaping the market daily.